Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis

Launched by QIANFOSHAN HOSPITAL · Jun 1, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at whether taking Staphylococcus albicans tablets for a long time can help people with bronchiectasis. Bronchiectasis is a condition that affects your lungs, making it hard to breathe and often leading to infections. The main goal of the study is to see if these tablets can reduce the number of flare-ups (or acute exacerbations) that patients experience. Additionally, the trial will check if these tablets can lower the chances of needing to go to the hospital and if they can improve the overall quality of life for patients. Researchers are also interested in how these tablets might help the immune system function better.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with bronchiectasis. You should have had at least two flare-ups in the past year. However, certain health conditions, such as cystic fibrosis, severe heart or liver disease, or being pregnant, may exclude you from joining. If you enroll, you can expect to take the tablets for a long period and attend regular check-ups to monitor your health and any changes you experience. This study is currently recruiting participants, so if you think you might be eligible, it could be a great opportunity to contribute to important research while potentially benefiting your health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;
• • Patients with idiopathic or post-infectious bronchiectasis;
• • 18years old;
• • Patients should have at least 2 acute exacerbations within 1 year before enrollment;
• • Patients in either acute exacerbation or stable period can be included.
• Exclusion Criteria:
• • Cystic fibrosis;
• • Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;
• • Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;
• • Still smoking;
• • Complicated with asthma or chronic obstructive disease Lung;
• • Patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage;
• • Malignant tumors;
• • Allergy to Staphylococcus albicans tablets;
• • Patients with a history of gastric ulcer or intestinal malabsorption;
• • Pregnant or lactating women;
• • patients with poor compliance;
• • previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, BCG, pneumonia vaccine and any kind of bacteria Extracts, such as Biostim, except for influenza vaccine) or immunosuppressants;
• • Patients who are participating in or have participated in interventional clinical trials within 3 months.